Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Timothy Garvey

Showing results (151-160 of 265) with videos related to

Pageof 27
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 3, 2016
EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALSPatrick M O'Neil, W Timothy Garvey, J Michael Gonzalez-Campoy, et al.
Kidney International|August 13, 2003
Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathyAlicia J Jenkins, Timothy J Lyons, Deyi Zheng, et al.
Hypertension (Dallas, Tex. : 1979)|December 2, 2025
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1Subodh Verma, Morten Böttcher, Paul Brown, et al.
Diabetes, Obesity & Metabolism|November 6, 2023
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysisEmily R Hankosky, Hui Wang, Lisa M Neff, et al.
Diabetes|January 24, 2003
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonanceW Timothy Garvey, Soonho Kwon, Deyi Zheng, et al.
Atherosclerosis|November 25, 2015
Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetesArpita Basu, Alicia J Jenkins, Ying Zhang, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 11, 2017
Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stressJoo Hyoung Lee, Minsung Kang, Hong Wang, et al.
The Lancet. Diabetes & Endocrinology|September 17, 2025
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trialIldiko Lingvay, Sara J Bergenheim, John B Buse, et al.
JAMA|January 11, 2022
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical TrialDomenica M Rubino, Frank L Greenway, Usman Khalid, et al.
Diabetes Care|March 7, 2020
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled TrialW Timothy Garvey, Andreas L Birkenfeld, Dror Dicker, et al.
Pageof 27

Showing results (151-160 of 265) with videos related to

Sort By:
Pageof 27
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 3, 2016
EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALSPatrick M O'Neil, W Timothy Garvey, J Michael Gonzalez-Campoy, et al.
Kidney International|August 13, 2003
Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathyAlicia J Jenkins, Timothy J Lyons, Deyi Zheng, et al.
Hypertension (Dallas, Tex. : 1979)|December 2, 2025
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1Subodh Verma, Morten Böttcher, Paul Brown, et al.
Diabetes, Obesity & Metabolism|November 6, 2023
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysisEmily R Hankosky, Hui Wang, Lisa M Neff, et al.
Diabetes|January 24, 2003
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonanceW Timothy Garvey, Soonho Kwon, Deyi Zheng, et al.
Atherosclerosis|November 25, 2015
Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetesArpita Basu, Alicia J Jenkins, Ying Zhang, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 11, 2017
Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stressJoo Hyoung Lee, Minsung Kang, Hong Wang, et al.
The Lancet. Diabetes & Endocrinology|September 17, 2025
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trialIldiko Lingvay, Sara J Bergenheim, John B Buse, et al.
JAMA|January 11, 2022
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical TrialDomenica M Rubino, Frank L Greenway, Usman Khalid, et al.
Diabetes Care|March 7, 2020
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled TrialW Timothy Garvey, Andreas L Birkenfeld, Dror Dicker, et al.
Pageof 27